PKD Clinical Trial - Approval to Escalate Dosing
Filed with ASX · · 4 pages · English
• The Company today announces that it is escalating dosing to the third cohort in Part B of the Single Ascending Dose (SAD) study being conducted in PKD patients • This progress follows approval from the Safety Review Committee (SRC) governing these clinical trials to continue dose escalation after the SRC reviewed the safety data for the first two cohorts of PKD patients dosed with PYC-003 in Par
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- Half Yearly Report and Accounts
- Retail Offer Booklet
- Completion of Placement and Institutional Entitlement Offer
- PYC Raising up to $653m to Deliver Human Efficacy Data
- PYC Capital Raising Presentation
Later from PYC Therapeutics
- Completion of Retail Entitlement Offer
- ADOA Program - SRC Approve Progression to Multi-Dose Study
- Presentation of Ophthalmology Clinical Trial Data at ARVO
- PKD - Initiation of Multiple Dose Clinical Trial
- ADOA Program Update
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics